HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GSK2245035

a Toll-like receptor 7 agonist

Also Known As:

6-amino-2-((1-methylbutyl)oxy)-9-(5-(1-piperidinyl)pentyl)-7,9-dihydro-8H-purin-8-one

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - GSK2245035: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        GSK2245035: 4

Experts

1.	Powley, W: 2 articles (09/2017 - 10/2015)
2.	Quint, D: 2 articles (09/2017 - 10/2015)
3.	Hohlfeld, Jens M: 1 article (01/2020)
4.	Lee, Laurie: 1 article (01/2020)
5.	Pandya, Hitesh: 1 article (01/2020)
6.	Powley, Will: 1 article (01/2020)
7.	Quint, Diana: 1 article (01/2020)
8.	Shabbir, Shaila: 1 article (01/2020)
9.	Siddall, Hilary: 1 article (01/2020)
10.	Singh, Dave: 1 article (01/2020)

Related Diseases

1.	Allergic Rhinitis 09/01/2017 - "Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial." 10/01/2015 - "Randomized, double-blind, placebo-controlled trials in healthy volunteers and patients with allergic rhinitis demonstrated that intranasal GSK2245035 doses <100 ng were tolerated and did not cause nasal inflammation. "
2.	Asthma (Bronchial Asthma) 01/01/2020 - "Although target engagement was observed, weekly intranasal GSK2245035 20 ng for 8 weeks did not substantially attenuate the late asthmatic response in participants with mild allergic asthma. " 01/01/2020 - "This double-blind, placebo-controlled, parallel-group Phase IIa trial randomized (1:1) participants with mild allergic asthma to intranasal GSK2245035 20 ng or placebo once weekly for 8 weeks; follow-up was conducted 1, 4, and 12 weeks after treatment. " 01/01/2020 - "This study investigated whether intranasal GSK2245035 reduced allergen-induced bronchial reactivity in mild allergic asthma. " 03/10/2016 - "Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma."
3.	Inflammation (Inflammations) 10/01/2015 - "Randomized, double-blind, placebo-controlled trials in healthy volunteers and patients with allergic rhinitis demonstrated that intranasal GSK2245035 doses <100 ng were tolerated and did not cause nasal inflammation. "
4.	Headache (Headaches) 01/01/2020 - "Adverse events were reported by 10/14 (71%) and 21/22 (95%) participants in the placebo and GSK2245035 groups, respectively; headache was the most common. " 09/01/2017 - "GSK2245035 induced CytoRS-AEs (most commonly headache, median duration <1 day) in 93% of participants at 80 ng, while AE incidence at 20 ng was similar to placebo. "

Related Drugs and Biologics

1.	Allergens
2.	Toll-Like Receptor 7

Related Therapies and Procedures

1.	Aftercare (After-Treatment)